Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)

被引：10
|
作者：
Zinzani, Pier Luigi
Delwail, Vincent
Paneesha, Shankara
Rule, Simon
Garcia-Sancho, Alejandro Martin
Marin-Niebla, Ana
Salles, Gilles
Sancho, Juan-Manuel
Vergote, Vibeke
Zilioli, Vittorio Ruggero
Zheng, Fred
DeMarini, Douglas J.
Jiang, Wei
Mehta, Amitkumar
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134609
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页数：4
相关论文
共 50 条
  • [1] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205)
    Mehta, Amitkumar
    Trneny, Marek
    Walewski, Jan
    Ribrag, Vincent
    Dartigeas, Caroline
    Christensen, Jacob Haaber
    Pane, Fabrizio
    Rodriguez, Guillermo
    Taszner, Michal
    Venugopal, Parameswaran
    Zilioli, Vittorio Ruggero
    Zheng, Fred
    DeMarini, Douglas J.
    Jiang, Wei
    Zinzani, Pier Luigi
    BLOOD, 2020, 136
  • [2] Efficacy and Safety of Parsaclisib in Patients With Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated With a BTK Inhibitor: Primary Analysis From a Phase 2 Study (CITADEL-205)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 11 - 13
  • [3] Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor: Primary Analysis from a Phase 2 Study (CITADEL-205)
    Mehta, Amitkumar
    Trneny, Marek
    Walewski, Jan
    Ribrag, Vincent
    Dartigeas, Caroline
    Christensen, Jacob Haaber
    Pane, Fabrizio
    Rodriguez, Guillermo
    Taszner, Michal
    Venugopal, Parameswaran
    Zilioli, Vittorio Ruggero
    Zheng, Fred
    DeMarini, Douglas J.
    Jiang, Wei
    Zinzani, Pier Luigi Luigi
    BLOOD, 2021, 138
  • [4] Parsaclisib, a PI3Kd inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study
    Zinzani, Pier Luigi
    Trneny, Marek
    Ribrag, Vincent
    Zilioli, Vittorio Ruggero
    Walewski, Jan
    Christensen, Jacob Haaber
    Delwail, Vincent
    Rodriguez, Guillermo
    Venugopal, Parameswaran
    Coleman, Morton
    Dartigeas, Caroline
    Patti, Caterina
    Pane, Fabrizio
    Jurczak, Wojciech
    Taszner, Michal
    Paneesha, Shankara
    Zheng, Fred
    Demarini, Douglas J.
    Jiang, Wei
    Gilmartin, Aidan
    Mehta, Amitkumar
    ECLINICALMEDICINE, 2023, 62
  • [5] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
    Lynch, Ryan C.
    Paneesha, Shankara
    Avigdor, Abraham
    McKinney, Matthew S.
    Wahlin, Bjorn E.
    Hrom, John S.
    Belada, David
    Canales, Miguel
    Cunningham, David
    Devizzi, Liliana
    Morley, Nicholas
    Zheng, Fred
    DeMarini, Douglas J.
    Jiang, Wei
    Trneny, Marek
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 11 - 12
  • [6] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
    Lynch, Ryan C.
    Paneesha, Shankara
    Avigdor, Abraham
    McKinney, Matthew S.
    Wahlin, Bjorn E.
    Hrom, John S.
    Belada, David
    Canales, Miguel
    Cunningham, David
    Devizzi, Liliana
    Morley, Nicholas
    Zheng, Fred
    DeMarini, Douglas J.
    Jiang, Wei
    Trneny, Marek
    BLOOD, 2020, 136
  • [7] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
    Phillips, Tycel J.
    Corradini, Paolo
    Gurion, Ronit
    Patti, Caterina
    Tani, Monica
    Avigdor, Abraham
    Jurczak, Wojciech
    Mehta, Amitkumar
    Zinzani, Pier Luigi
    Lossos, Izidore S.
    Thieblemont, Catherine
    Zheng, Fred
    Rappold, Erica
    Zhao, Wanying
    Johnson, Peter
    BLOOD, 2020, 136
  • [8] Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
    Maruyama, Dai
    Nagai, Hirokazu
    Fukuhara, Noriko
    Kitano, Toshiyuki
    Ishikawa, Takayuki
    Shibayama, Hirohiko
    Choi, Ilseung
    Hatake, Kiyohiko
    Uchida, Toshiki
    Nishikori, Momoko
    Kinoshita, Tomohiro
    Matsuno, Yoshihiro
    Nishikawa, Tomoaki
    Takahara, Satoko
    Tobinai, Kensei
    CANCER SCIENCE, 2016, 107 (12) : 1785 - 1790
  • [9] Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203)
    Lynch, Ryan C.
    Avigdor, Abraham
    McKinney, Matthew S.
    Paneesha, Shankara
    Wahlin, Bjorn
    Hrom, John S.
    Cunningham, David
    Morley, Nicholas
    Canales, Miguel
    Bastos-Oreiro, Mariana
    Belada, David
    Devizzi, Liliana
    Zheng, Fred
    DeMarini, Douglas J.
    Jiang, Wei
    Trneny, Marek
    BLOOD, 2021, 138
  • [10] Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204)
    Phillips, Tycel
    Avigdor, Abraham
    Gurion, Ronit
    Patti, Caterina
    Corradini, Paolo
    Tani, Monica
    Mehta, Amitkumar
    Lossos, Izidore S.
    Lossos, Izidore S.
    Zinzani, Pier Luigi Luigi
    Thieblemont, Catherine
    Jurczak, Wojciech
    Zheng, Fred
    Rappold, Erica
    Zhao, Wanying
    Johnson, Peter
    BLOOD, 2021, 138
12345